Clinical Trials
22 trialsNCT05355701 2026-06-05
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT05538130 2026-06-05
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT07244835 2026-05-13
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Phase 1 Recruiting
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT05907304 2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT06771219 2026-01-23
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
Phase 1 Recruiting
NCT06336148 2025-10-15
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Phase 1 Terminated
NCT06270082 2025-09-19
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Ikena Oncology
Phase 1 Terminated
NCT05241834 2025-09-04
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04706962 2025-04-15
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
Phase 1 Active not recruiting
NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
NCT02628535 2022-02-08
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Phase 1 Terminated
NCT02012231 2020-10-19
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Fore Biotherapeutics
Phase 1 Terminated
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT02313012 2019-11-18
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
Celgene
Phase 1 Terminated
NCT02456701 2017-09-05
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Celldex Therapeutics
Phase 1 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00689065 2013-11-01
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Calando Pharmaceuticals
Phase 1 Terminated
NCT00215605 2013-02-27
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Exelixis
Phase 1 Completed
NCT00423254 2010-08-03
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Phase 1 Completed